Pharmaceutical

UI-059 by Korea United Pharm for Reflux Esophagitis (Gastroesophageal Reflux Disease): Likelihood of Approval

UI-059 is under clinical development by Korea United Pharm and currently in Phase I for Reflux Esophagitis (Gastroesophageal Reflux Disease).

Dec 20, 2023 - 18:00
UI-059 is under clinical development by Korea United Pharm and currently in Phase I for Reflux Esophagitis (Gastroesophageal Reflux Disease).
Read the original article

Tags:

Previous Article

GLB-001 by GluBio Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

Next Article

GUB-014295 by Gubra for Obesity: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Women spend 20% more per year on out-of-pocket health costs, says report

Women spend 20% more per year on out-of-pocket health c...

Sep 30, 2023

Concentric Analgesics highlights data on vocacapsaicin for pain relief

Concentric Analgesics highlights data on vocacapsaicin ...

Aug 7, 2024

STAT+: Devoted Health’s losses in Medicare Advantage persist

STAT+: Devoted Health’s losses in Medicare Advantage pe...

Feb 5, 2024